Tirzepatide shows stronger long-term metabolic results in new analysis
A multi-year review compares two generations of GLP-1 peptides.
by Editorial team
What the analysis covered
An independent team pooled outcomes data from 14 studies covering roughly 11,000 participants who used either semaglutide or tirzepatide over 12 to 36 months. The goal was to compare long-term metabolic markers — not just short-term weight loss.
Headline findings
Tirzepatide users showed roughly 22% greater average reduction in HbA1c at the 24-month mark compared to semaglutide users at equivalent doses. Weight outcomes also favored tirzepatide, with a larger fraction of users maintaining loss past year two.
Importantly, drop-off rates due to side effects were similar between the two, suggesting the gap is not explained by tolerability differences.
Caveats
Pooled analyses are not the same as a head-to-head trial. Study populations, dosing schedules, and outcome definitions varied. The authors flag this clearly in their limitations section.
None of this is medical advice. If you're discussing GLP-1 options with a clinician, share this paper — don't replace the conversation with it.